View On Demand

How Kineta Is Ushering In A New Era Of Immunotherapy

About the Event

Kineta (NASDAQ: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies. Their novel drug programs are focused on addressing and correcting immuno-suppression, exhausted T-cells, and poor tumor immune response.

Kineta entered into a clinical trial collaboration and supply agreement with Merck to evaluate KVA12123, a monoclonal antibody that binds to VISTA, a key driver of immunosuppression.

The trial will look at KVA12123 alone and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). It is targeting several cancer types with an estimated total addressable market eclipsing $25B.

Join this webinar with Kineta CEO, Shawn Iadonato and John Vandermosten, Senior Biotechnology Analyst, Zacks Investment Research, to learn more about their partnership with Merck and what it could mean for the future of cancer therapy.

Sign Up Today


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.